Dana M. Chase, MD

Dana Chase, MD

(she/her)

Associate Professor, Department of Obstetrics and Gynecology/Gynecologic Oncology

Languages

English

Education

Fellowship

Gynecologic Oncology, University of California, Irvine, Orange, CA, 2011

Degrees

MD, University of California, Irvine, Orange, CA, 2003
Post-Bacc, Columbia University, New York, NY, 1999
BA, Brown University, Providence, RI, 1996

Residency

Obstetrics and Gynecology, University of California, Irvine, Orange, CA, 2007

Board Certifications

Gynecologic Oncology, American Board of Obstetrics and Gynecology, 2014
Obstetrics and Gynecology, American Board of Obstetrics and Gynecology, 2009

Contact Information

Scientific Interests

Dr. Chase's cancer-relevant research interests have included: translational research collaboration involving the vaginal microbiome and metabolites in endometrial and cervical cancer, research regarding implicit bias in gynecologic oncology, treatment patterns and outcomes in older women with gynecologic cancers, symptom management and quality of life, and as a co-principal investigator in Phase II or III clinical trials in the gynecologic cancer space.

Highlighted Publications

Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M,Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW,Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapyin the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRGOncology Group study. Int J Gynecol Cancer. 2020 May;30(5):596-601. doi: 10.1136/ijgc-2019-000869. Epub 2020 Feb 28. Erratum in: Int J Gynecol Cancer. 2020 Aug;30(8):1267. PMID:32114513; PMCID: PMC7780262.

Chase DM, Neighbors J, Perhanidis J, Monk BJ. Gastrointestinal symptoms and diagnosispreceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. Gynecol Oncol. 2021 Jun;161(3):832-837. doi: 10.1016/j.ygyno.2021.03.021. Epub 2021 Apr 1.PMID: 33814195.

Łaniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, Chase DM, Roe DJ, Herbst-Kralovetz MM. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer.Biomark Res. 2022 Dec 2;10(1):88. doi: 10.1186/s40364-022-00438-5. PMID: 36461062;PMCID: PMC9717501.

Kaelin EA, Skidmore PT, Łaniewski P, Holland LA, Chase DM, Herbst-Kralovetz MM, Lim ES.Cervicovaginal DNA Virome Alterations Are Associated with Genital Inflammation and Microbiota Composition. mSystems. 2022 Mar 28:e0006422. doi: 10.1128/msystems.00064-22.Epub ahead of print. PMID: 35343798.

Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'MalleyDM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A; PRIMA/ENGOT-OV26/GOG-3012Investigators. Impact of disease progression on health-related quality of life of advanced ovariancancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 Sep;166(3):494-502.doi: 10.1016/j.ygyno.2022.06.028. Epub 2022 Jul 15. PMID: 35851489.